Roche Buys IL-2 Technology From Good, Which Forms New Firm Bonum

 
• By Jessica Merrill

Roche is paying $250m up front to buy Good Therapeutics, which will launch a new company, Bonum Therapeutics, to explore its platform technology for targets other than interleukin-2.

off and on
Good's technology can turn up therapeutic activity where it is needed • Source: Shutterstock

More from Deals

More from Business